000160357 001__ 160357
000160357 005__ 20180913060236.0
000160357 0247_ $$2doi$$a10.1007/s00418-008-0530-8
000160357 02470 $$2ISI$$a000261956400004
000160357 037__ $$aARTICLE
000160357 245__ $$aThe tumor microenvironment and its contribution to tumor evolution toward metastasis
000160357 269__ $$a2008
000160357 260__ $$c2008
000160357 336__ $$aReviews
000160357 520__ $$aCancer cells acquire cell-autonomous capacities to undergo limitless proliferation and survival through the activation of oncogenes and inactivation of tumor suppressor genes. Nevertheless, the formation of a clinically relevant tumor requires support from the surrounding normal stroma, also referred to as the tumor microenvironment. Carcinoma-associated fibroblasts, leukocytes, bone marrow-derived cells, blood and lymphatic vascular endothelial cells present within the tumor microenvironment contribute to tumor progression. Recent evidence indicates that the microenvironment provides essential cues to the maintenance of cancer stem cells/cancer initiating cells and to promote the seeding of cancer cells at metastatic sites. Furthermore, inflammatory cells and immunomodulatory mediators present in the tumor microenvironment polarize host immune response toward specific phenotypes impacting tumor progression. A growing number of studies demonstrate a positive correlation between angiogenesis, carcinoma-associated fibroblasts, and inflammatory infiltrating cells and poor outcome, thereby emphasizing the clinical relevance of the tumor microenvironment to aggressive tumor progression. Thus, the dynamic and reciprocal interactions between tumor cells and cells of the tumor microenvironment orchestrate events critical to
000160357 6531_ $$aTumor microenvironment
000160357 6531_ $$aInflammation
000160357 6531_ $$aAngiogenesis
000160357 6531_ $$aTumor progression
000160357 6531_ $$aMetastasis
000160357 6531_ $$aCancer Stem-Cells
000160357 6531_ $$aImmune-Response
000160357 6531_ $$aBreast-Cancer
000160357 6531_ $$aChronic Inflammation
000160357 6531_ $$aStromal Fibroblasts
000160357 6531_ $$aTherapeutic Target
000160357 6531_ $$aAngiogenic Switch
000160357 6531_ $$aDrug-Resistance
000160357 6531_ $$aVascular Niche
000160357 6531_ $$aSolid Tumors
000160357 700__ $$aLorusso, Girieca
000160357 700__ $$aRuegg, Curzio
000160357 773__ $$j130$$q1091-1103$$tHistochemistry And Cell Biology
000160357 909C0 $$0252372$$pSV$$xU10445
000160357 909CO $$ooai:infoscience.tind.io:160357$$pSV$$preview
000160357 917Z8 $$xWOS-2010-11-30
000160357 937__ $$aEPFL-REVIEW-160357
000160357 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000160357 980__ $$aREVIEW